Guide
Endoscopic Procedures to “Lock In” GLP-1 Weight Loss: Early Data, Big Caveats
Early sham-controlled work has tested endoscopic procedures intended to preserve weight loss after stopping a GLP-1, with encouraging retention figures reported. It is ea
Early sham-controlled work has tested endoscopic procedures intended to preserve weight loss after stopping a GLP-1, with encouraging retention figures reported. It is early-stage, not standard care, and the honest framing is a research signal rather than an option available to most patients.
What does the evidence actually show?
| Field | Status | Comment |
|---|---|---|
| Study design | Sham-controlled | A strength |
| Reported outcome | High retention of loss after stopping | Encouraging |
| Sample size and duration | Small, short | The main limitation |
| Standard of care | No | Not routine practice |
| Long-term safety | Not established | Requires longer follow-up |
The regain problem is real and well documented, so a procedure that addresses it is genuinely interesting. That is exactly why it attracts overstatement.
A sham-controlled trial is a real strength, and small size with short follow-up is a real limitation. Both are true. Anyone presenting this as an available solution to GLP-1 discontinuation is ahead of the evidence, and anyone dismissing it is ignoring a controlled result.
The practical position for now: the established answer to regain after stopping is continued treatment, which is why annual maintenance cost is the figure that matters when comparing programmes.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does treatment cost while this is true?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is there a procedure that locks in GLP-1 weight loss?
Early sham-controlled work has tested endoscopic procedures intended to preserve loss after stopping, with encouraging retention reported. It is early-stage and not standard care.
Should I consider one instead of staying on treatment?
The established answer to regain after stopping is continued treatment. The procedural data is a research signal, not an available alternative for most patients.
What is the main limitation of the evidence?
Small sample size and short follow-up, with long-term safety not established, despite the strength of a sham-controlled design.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- What Happens After You Stop Tirzepatide?Journal
- SUMMIT Trial: Tirzepatide and HFpEFResearch
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- Retatrutide Phase 3 Results and How It ComparesResearch
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money
- Monthly vs Prepaid GLP-1 ProgramsComparisons
Related coverage
GLP-1 Tirzepatide Rank. “Endoscopic Procedures to “Lock In” GLP-1 Weight Loss: Early Data, Big Caveats.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/glp1-gut-procedures-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.